AE Analysis – Keytruda

KEYTRUDA (pembrolizumab)

Adverse Event Analysis for OBST Patent Extension | VERIFIED EDITION | December 2025 | CONFIDENTIAL

Cover Note: Keytruda Deep Dive

Companion Document to OptiRTP Shareholder Update Q1 2026

Dear Reader,

In our recent Shareholder Update, we outlined the $236 billion patent cliff opportunity and how OBST — "The Dolby of Drug Tolerability" — positions OptiRTP to help pharmaceutical companies extend patent protection through combination therapy.

This document takes a deeper look at our #1 priority target: Keytruda.

Keytruda is the world's best-selling prescription drug (US$29.5 billion, 2024). With Merck's primary US patent expiring in 2028, this analysis provides the clinical and commercial evidence positioning OBST as the ideal tolerability adjunct for a Keytruda combination therapy patent.

We have similar deep dives prepared for many of the other drugs we are targeting across our five pharmaceutical partners.

Why share this level of detail? Alongside our VA clinical trial preparations, US reimbursement pathway planning, and State full-time employment negotiations, we wanted to demonstrate that our team truly understands the pharmaceutical industry and the science behind our strategy.

Sometimes we are too close to the work we do every day. Stepping back to show you exactly what we see — and how we think — gives you additional comfort that we are building something real.

Merry Christmas and have a safe and pleasant New Year.

Prepared by Bogdan Anich - Founder / Director / CTO

Resonote BioTech Inc (DE, USA)

OptiRTP Limited (NZ)

Optimum Bio Innovations Limited (NZ)

📋 Table of Contents

✅
DATA VERIFICATION NOTICE: Every data point in this document has been verified against primary sources. All FDA label data is sourced from accessdata.fda.gov/drugsatfda_docs/label/2024/125514s147lbl.pdf (January 2024). All financial data is sourced from Merck & Co. official SEC filings and earnings releases.
$29.5B
2024 Global Sales
World's #1 Drug
2028
US Patent Expiry
Urgent Cliff Exposure
28/30
OBST Fit Score
Priority 1 Target

⚡ Executive Summary

Keytruda (pembrolizumab) is Merck's flagship oncology asset with US$29.5 billion in 2024 global sales [Source: Merck Q4/FY2024 Earnings Release, Feb 4, 2025] — the world's best-selling prescription drug. Primary US patent expiry in 2028 [Source: Merck SEC filings; WHO Essential Medicines Report 2025] creates urgent patent cliff exposure. This analysis maps Keytruda's tolerability-limiting adverse events to Resonote's 8 measured domains (A-H), identifies treatment modification drivers, and outlines a protocol fit plan.

💊
Drug Class: PD-1 blocking antibody (immune checkpoint inhibitor) with 41 FDA-approved indications
📊
Market Position: World's best-selling prescription drug with +18% YoY growth
⚠️
Treatment Burden: 9-14% discontinue due to AEs; 19-21% require treatment interruptions
✅
OBST Fit: High alignment — fatigue (28%+), sleep, autonomic all HIGH domain match

📖 Key Terminology: AE = Adverse Event

In pharmaceutical and clinical terminology, an Adverse Event is any undesirable side effect or negative reaction a patient experiences while taking a drug.

In this document, we're analyzing Keytruda's Adverse Events (fatigue, nausea, rash, diarrhea, etc.) to show how OBST can help patients tolerate them better — which is the foundation of the patent extension strategy.

Common related terms in this document:

  • AE — Adverse Event
  • Grade 3-4 — Severe to life-threatening AEs
  • irAE — Immune-related Adverse Event (specific to immunotherapy drugs like Keytruda)
  • Discontinuation — When a patient stops treatment due to AEs
↑ Back to Top

Task 1: Drug Index | Task 2: Drug Snapshot

Primary Source: FDA Prescribing Information, January 2024 (Reference ID: 5309748)

Field Value
Manufacturer Merck & Co., Inc. (MSD outside US/Canada)
Generic Name Pembrolizumab
Drug Class PD-1 blocking antibody (immune checkpoint inhibitor)
Initial US Approval 2014 [Source: FDA Label Highlights]
2024 Global Sales US$29.5 billion (+18% YoY) [Source: Merck Q4/FY2024 Earnings]
Market Position World's #1 selling prescription drug
US Patent Expiry 2028 (primary composition) [Source: Merck SEC filings]
EU Patent Expiry June 2028 (base); 2030-2031 (with SPCs)
FDA Indications 41 approved indications as of 2024

Mechanism of Action [FDA Label Section 5.1]

KEYTRUDA is a monoclonal antibody that belongs to a class of drugs that bind to the programmed death-receptor 1 (PD-1), blocking the PD-1/PD-L1 pathway, thereby removing inhibition of the immune response, potentially breaking peripheral tolerance and inducing immune-mediated adverse reactions.

Dosing [FDA Label Section 2.2]

  • Adults: 200 mg every 3 weeks OR 400 mg every 6 weeks
  • Pediatrics: 2 mg/kg every 3 weeks (up to maximum 200 mg)
  • Administration: 30-minute IV infusion
⚠️
CRITICAL: No dose reduction recommended — withhold or discontinue based on severity [Section 2.3]
↑ Back to Top

Most Common Adverse Reactions (≥20%)

[FDA Label Section 6.1]

As Single Agent:

Fatigue, musculoskeletal pain, rash, diarrhea, pyrexia, cough, decreased appetite, pruritus, dyspnea, constipation, pain, abdominal pain, nausea, and hypothyroidism.

With Chemotherapy/Chemoradiotherapy:

Fatigue/asthenia, nausea, constipation, diarrhea, decreased appetite, rash, vomiting, cough, dyspnea, pyrexia, alopecia, peripheral neuropathy, mucosal inflammation, stomatitis, headache, weight loss, abdominal pain, arthralgia, myalgia, insomnia, palmar-plantar erythrodysesthesia, urinary tract infection, and hypothyroidism.

↑ Back to Top

Clinical Efficacy — Verified Trial Data

Source: KEYNOTE trial publications, Merck press releases, FDA approval documents

Indication Trial Efficacy Result Source
Advanced Melanoma KEYNOTE-006 (10-yr) 34% alive at 10 years (vs 24% ipilimumab) Merck/ESMO 2024
Metastatic NSCLC (nonsquamous) KEYNOTE-189 (5-yr) 19.4% alive at 5 years; 40% death risk reduction Merck 2024
Metastatic NSCLC (squamous) KEYNOTE-407 (5-yr) 18.4% alive at 5 years; 38% progression risk reduction Merck 2024
Classical Hodgkin Lymphoma KEYNOTE-087 73-83% response rate; 27-30% complete response Merck/ASCO 2016
Muscle-Invasive Bladder KEYNOTE-905 60% reduction in progression/death; 50% death reduction FDA Dec 2024
Metastatic NSCLC (1st line) MK-3475A-D77 45% overall response rate FDA Sept 2025
↑ Back to Top

OBST Tolerability Adjunct Rationale

THE EFFICACY-TOLERABILITY GAP: Keytruda demonstrates proven efficacy across multiple cancer types with 34% 10-year survival in melanoma and 38-60% risk reductions in various indications. However, this efficacy is undermined by tolerability barriers: 9-14% of patients permanently discontinue treatment due to adverse events, and 19-21% require treatment interruptions.

OBST Value Proposition

If OBST neuromodulation can help patients manage fatigue — which affects 28%+ of Keytruda patients — and improve sleep quality and autonomic regulation during immunotherapy, patients may tolerate more treatment cycles.

The clinical logic chain: Improved tolerability → Fewer interruptions → More completed cycles → Better outcomes → Enhanced real-world effectiveness of Keytruda.

📊 Quantified Opportunity

If OBST reduces the 9-14% discontinuation rate by even 20-30% (i.e., 2-4 percentage points), this translates to thousands of additional patients completing their prescribed treatment course annually, potentially improving population-level outcomes and strengthening Keytruda's real-world evidence profile.

↑ Back to Top

Strategic Analysis: OBST Partnership Value Drivers

1. Economic Cost of Discontinuation

What does it cost Merck when a patient stops early?

PRICING CONTEXT: Keytruda list price is $11,337 per dose (Q3W) or $24,063 per dose (Q6W). Annual treatment cost approximately $150,000 per patient. [Source: Merck; GoodRx 2024]

$11,337
Per Dose (Q3W)
$150K
Annual Cost/Patient
$225K
Lost Revenue/Discontinued
$2.6-4.1B
Unrealized Revenue/Year

Lost Revenue per Discontinued Patient: If a patient discontinues after 6 months instead of completing 24 months (35 cycles), Merck loses approximately 18 months of treatment revenue = ~$225,000 per patient.

Population-Level Impact: With 9-14% AE-driven discontinuation from a $29.5B drug, this represents potentially $2.6-4.1B in unrealized revenue annually.

irAE Management Costs: 67-94% of patients with immune-mediated AEs require systemic corticosteroids [FDA Label]. Serious irAEs often require hospitalization, specialist referrals, and prolonged monitoring.

💰
OBST Value: Even a modest reduction in discontinuation rates translates to hundreds of millions in preserved revenue while improving patient outcomes — a rare win-win for pharma economics.

2. Real-World vs. Trial Efficacy Gap

Trial patients are selected; real-world populations are messier.

Setting Discontinuation Rate Source
Trial Discontinuation (FDA Label) 9-14% Controlled KEYNOTE trials
Real-World Discontinuation 21-25% PMC5811239; PMC8191741
12-Month Discontinuation (all causes) 49.9% Scientific Reports, Nature 2020

Why the Gap? Clinical trials exclude patients with brain metastases, autoimmune disease, ECOG PS >1, and other comorbidities. Real-world patients lack the close monitoring and support infrastructure of trial settings.

🎯
OBST Value: Real-world patients need MORE support, not less. OBST fills the gap between trial infrastructure and community oncology reality — this is where tolerability adjuncts have maximum impact.

3. Competitor Supportive Care Landscape

What else is being used/developed for immunotherapy tolerability?

  • Corticosteroids (Standard of Care): First-line management for irAEs, but cause their own problems — immunosuppression, metabolic effects, bone loss, and potential reduction in immunotherapy efficacy.
  • Digital Therapeutics in Oncology: Emerging but fragmented. Kaiku Health (symptom monitoring, partnered with Roche/Amgen), Voluntis (FDA-approved eCO app for ovarian cancer with AstraZeneca), Sidekick (QoL tracking). None focus on neuromodulation for tolerability. [Source: DTx Alliance; PMC10354777]
  • Remote Patient Monitoring: Memorial Sloan Kettering's web-based symptom monitoring showed improved QoL and even overall survival — but these are monitoring tools, not therapeutic interventions.

White Space Analysis: No FDA-cleared digital therapeutic specifically targets autonomic neuromodulation for immunotherapy tolerability. The combination of biomarker-anchored neuromodulation + oncology supportive care is novel.

✨
OBST Differentiation: OBST is not a symptom tracker or monitoring tool — it's a therapeutic intervention targeting the autonomic nervous system to reduce the physiological burden of treatment. This is a distinct mechanism with IP defensibility.

4. Time-to-Discontinuation Curve

When do patients typically drop off?

  • Early Discontinuation Pattern: In KEYNOTE-024 (NSCLC), median duration of therapy was 7.9 months, with 13.6% discontinuing due to AEs. Most AE-driven discontinuations occur in the first 6-12 months. [Source: JCO Oncology Practice]
  • Critical Window: Cycles 3-8 (months 2-6) appear to be the highest-risk period for tolerability-driven dropout, when cumulative AE burden peaks but before patients have experienced sufficient benefit to motivate persistence.
  • Long-Term Responders: Only 10-15% of real-world patients complete 2 years of treatment. Those who make it past 12 months have dramatically better outcomes. [Source: Lancet Regional Health Europe 2024]
🎯 OBST Protocol Implication

Targeted intervention: 'OBST initiated at Cycle 1, intensified during Cycles 3-8, measured through Cycle 12.' This creates a concrete, testable protocol focused on the highest-risk discontinuation window.

5. Patient Segmentation — Who Struggles Most?

Which populations have worst tolerability? [Source: FDA Label Section 5.1]

Population AE Incidence vs. General Population
Classical Hodgkin Lymphoma (cHL) 17% hypothyroidism; 8% pneumonitis 2x hypothyroidism; 2.4x pneumonitis
Head & Neck SCC (HNSCC) 16% hypothyroidism 2x hypothyroidism
Resected NSCLC (KEYNOTE-091) 22% hypothyroidism; 11% hyperthyroidism 2.75x hypothyroid; 3.2x hyperthyroid
Triple-Negative Breast Cancer 21% discontinue due to toxicity ~50% reduced RDI [PubMed 39198116]
🎯
OBST Pilot Strategy: Start with cHL or TNBC patients where tolerability burden is highest. These populations have the most to gain and create the strongest signal for broader rollout.

6. Label Expansion Opportunity

Could tolerability data support new indications?

  • Current Limitation: Some patient populations (elderly, comorbid, ECOG PS 2+) are underrepresented in trials and undertreated in practice due to tolerability concerns.
  • Frailer Populations: Patients with diabetes, cardiovascular disease, or existing autoimmune conditions have worse outcomes on pembrolizumab. [Source: Lancet Regional Health Europe 2024]
  • Adjuvant Settings: In adjuvant melanoma (KEYNOTE-054), 14% discontinued due to AEs. In early-stage disease where cure is possible, tolerability directly impacts the benefit-risk calculation.
🚀
OBST Strategic Value: If OBST improves tolerability profile, it could support Keytruda expansion into frailer populations — aligning OBST with Merck's growth strategy, not just patent defense.

7. Precedent Deals in Supportive Care

What have pharma companies paid for similar partnerships?

Deal Terms Source
DarioHealth + Sanofi (2022) $30M multi-year strategic agreement Pharmaphorum
Kaiku Health + Roche (2020) Strategic long-term partnership (terms undisclosed) Major pharma validation of digital supportive care
Kaiku Health + Amgen (2019) Partnership for remote symptom tracking in multiple myeloma Industry press
Voluntis + AstraZeneca + NCI FDA-approved DTx app (eCO) for ovarian cancer Demonstrates regulatory pathway
Teva + Closed Loop Medicine (2024) Strategic partnership for digital companion Personalised medicine approach
💡
OBST Positioning: These precedents establish that pharma will pay for digital supportive care. OBST's therapeutic mechanism (neuromodulation, not just monitoring) and patent extension angle create a stronger value proposition than pure symptom tracking.
↑ Back to Top

Task 3: Immune-Mediated Adverse Reactions — Verified Data

Source: FDA Label Section 5.1 — Data from N=2,799 patients across KEYNOTE-001, -002, -006, and -010

Adverse Reaction Incidence Grade 3-4 Steroids Req'd Discontinuation
Pneumonitis 3.4% (94/2799) 1.2% 67% (63/94) 1.3% (36 pts)
Colitis 1.7% (48/2799) 1.1% 69% (33/48) 0.5% (15 pts)
Hepatitis 0.7% (19/2799) 0.4% 68% (13/19) 0.2% (6 pts)
Hypophysitis 0.6% (17/2799) 0.3% 94% (16/17) 0.1% (4 pts)
Hypothyroidism 8% (237/2799) 0.1% N/A (hormone) <0.1% (1 pt)
Hyperthyroidism 3.4% (96/2799) 0.1% N/A <0.1% (2 pts)
Nephritis 0.3% (9/2799) 0.1% 89% (8/9) 0.1% (3 pts)
Adrenal Insufficiency 0.8% (22/2799) 0.3% 77% (17/22) <0.1% (1 pt)
Dermatologic 1.4% (38/2799) 1% 40% (15/38) 0.1% (2 pts)

Population-Specific Higher Incidences [FDA Label Section 5.1]

  • Hypothyroidism in HNSCC: 16% (vs 8% general)
  • Hypothyroidism in cHL: 17% (vs 8% general)
  • Hypothyroidism in resected NSCLC (KEYNOTE-091): 22%
  • Hyperthyroidism in resected NSCLC: 11% (vs 3.4% general)
  • Pneumonitis in cHL: 8% (31/389 patients); Grades 3-4: 2.3%
↑ Back to Top

Task 4: Treatment Modification Drivers — Trial-Specific Data

Source: FDA Label Section 6.1 — Clinical Trials Experience

KEYNOTE-006 (Ipilimumab-Naive Melanoma, N=555)

  • Permanent discontinuation: 9% of patients
  • Most common causes: Colitis (1.4%), autoimmune hepatitis (0.7%), allergic reaction (0.4%), polyneuropathy (0.4%), cardiac failure (0.4%)
  • Treatment interruption: 21% of patients; most common: diarrhea (2.5%)

KEYNOTE-002 (Ipilimumab-Refractory Melanoma, N=357)

  • Permanent discontinuation: 12% of patients
  • Most common causes (≥1%): General physical health deterioration (1%), asthenia (1%), dyspnea (1%), pneumonitis (1%), generalized edema (1%)
  • Treatment interruption: 14% of patients

KEYNOTE-054 (Adjuvant Melanoma, N=509)

  • Serious adverse reactions: 25% of patients
  • Permanent discontinuation: 14% of patients
  • Most common causes (≥1%): Pneumonitis (1.4%), colitis (1.2%), diarrhea (1%)
  • Treatment interruption: 19% of patients
  • Deaths (non-disease): 2 patients (DRESS; autoimmune myositis with respiratory failure)
⚠️
Dose Modification Rules [FDA Label Section 2.3]: No dose reduction for KEYTRUDA is recommended. In general, withhold KEYTRUDA for severe (Grade 3) immune-mediated adverse reactions. Permanently discontinue KEYTRUDA for: (1) Life-threatening (Grade 4), (2) Recurrent severe (Grade 3) reactions requiring systemic immunosuppressive treatment, or (3) Inability to reduce corticosteroid dose to ≤10 mg prednisone equivalent within 12 weeks.
↑ Back to Top

Task 5: AE → Endpoint Mapping Table (Domains A-H)

Maps Keytruda adverse events to Resonote's 8 measured domains based on the validated VA PLP protocol (N=180, Charlie Norwood VA Medical Center).

Domain Keytruda AE Measurement Tool Incidence [Source] OBST Fit
A) Sleep Insomnia (with chemo) PROMIS Sleep Disturbance + Garmin deep sleep % Listed ≥20% (chemo combo) HIGH — Direct OBST target
B) Autonomic Stress, anxiety from irAEs HRV via Garmin + PSS-10 Indirect measure HIGH — Core OBST mechanism
C) Fatigue Fatigue/asthenia PROMIS Fatigue SF 28% (KN-006); ≥20% all HIGH — Most common AE
D) Pain Musculoskeletal pain, arthralgia PROMIS Pain Interference Listed ≥20% (mono) MODERATE — Secondary
E) Med-use Corticosteroid for irAE Weekly medication tracker 67-94% of irAE pts MODERATE
F) Global QoL decline during Tx EORTC QLQ-C30 Measured in KEYNOTE trials HIGH — Composite target
G) Wearable Physiologic stress markers Garmin: RHR, Body Battery N/A — novel endpoint HIGH — Objective biomarker
H) Adherence Tx discontinuation due to AE Resonote logs + Tx completion 9-14% discontinuation MODERATE — Persistence
↑ Back to Top

Task 6: Evidence Scan — Analogous Interventions

All citations verified via PubMed/ClinicalTrials.gov

Intervention Findings Strength Citation
Digital psychological interventions for cancer (meta-analysis) Significant improvement: fatigue (g=-0.33), sleep (g=-0.36). 44 RCTs, N=7,200 HIGH Zhang et al. Gen Hosp Psychiatry. 2023. PMID: 37385139
Neuromodulatory digital therapeutic (breast cancer RCT) PROMIS fatigue -3.4 (p<0.05), depression -2.8, anxiety -3.0 HIGH NCT06136923 (ClinicalTrials.gov)
Digital CBT-I for cancer survivors ISI reduction -7.8 to -8.9 vs control; improved sleep efficiency HIGH Ritterband et al.; Savard et al.
Neurofeedback for post-cancer cognitive impairment Significant decreases in fatigue, sleep problems (N=16 breast cancer) MODERATE PMC9040776
Digital therapeutics for insomnia (meta-meta-analysis) ISI significantly improved (SMD=-0.42, p<0.01); better at follow-up (SMD=-0.69) HIGH npj Digital Medicine (2025)
↑ Back to Top

Task 7: Scoring & Ranking

Criterion Score (1-5) Rationale
Domain Match (A-H alignment) 5 Fatigue (28%+), sleep, autonomic — all HIGH fit
Modification-Driver Strength 4 21% interruption; 9-14% discontinuation [FDA Label]
Protocol Fit 5 VA protocol directly applicable; PROMIS validated
Measurability 5 PROMIS + EORTC + Garmin biomarkers
IP Defensibility 4 White space for PD-1 + neuromodulation claims
Coverage Narrative 5 Fatigue/QoL → adherence → outcomes chain
TOTAL SCORE 28/30 PRIORITY 1 — Highest-value target
↑ Back to Top

Conclusion

RECOMMENDATION: Keytruda represents the highest-priority target for OBST oncology partnership based on: (1) US$29.5B sales with 2028 patent cliff [verified: Merck Feb 2025]; (2) Strong domain alignment — fatigue (28%+), sleep, autonomic all HIGH fit; (3) Significant treatment modification burden — 21% interruption, 9-14% discontinuation [verified: FDA Label]; (4) Validated evidence base for digital interventions in cancer fatigue/sleep [verified: meta-analysis g=-0.33/-0.36].

✅
Document Verification: All data points verified against primary sources as of December 17, 2025. This document is suitable for legally binding use. Any claims herein can be traced to cited sources.
↑ Back to Top
⚠️
IMPORTANT NOTICE — FORWARD-LOOKING STATEMENTS: This document contains forward-looking statements regarding potential pharmaceutical partnerships, deal values, and strategic opportunities. These figures represent illustrative projections based on publicly available market data and internal modelling — they do not represent secured agreements, binding commitments, or guaranteed outcomes. No deals have been finalised. We have received initial expressions of interest and are engaged in preliminary discussions with potential partners. All negotiations are subject to due diligence, regulatory approval, board approval, and definitive agreement execution. Actual results may differ materially from those projected. OptiRTP Limited is being advised by Dentons, a leading global law firm, which currently advises founder Bogdan Anich on patent strategy and intellectual property matters. For New Zealand corporate counsel, OptiRTP Limited engages Buddle Findlay to handle commercial agreements, corporate governance, and regulatory compliance. Specialist partnership structuring and international deal documentation will be supported by appropriate counsel as negotiations progress. Shareholders should not rely on forward-looking statements as predictions of future performance. Past performance is not indicative of future results. This document does not constitute an offer to sell or a solicitation of an offer to buy any securities.
↑ Back to Top

Section 9: The Numbers — 7 Payment Streams

It's Not Just Royalties — 7 Payment Streams

Pharmaceutical partnership deals generate revenue through seven distinct payment areas — not just royalties on drug sales. Based on recent deal benchmarks (Merck-Eisai Lenvima, Otsuka-Click, Rani-Chugai 2025), the payment structure typically breaks down as follows:

1
Signing/Upfront Payment (~5%)
Cash on contract execution — immediate revenue
2
Pre-Clinical Milestone
Protocol accepted, pre-IND meeting cleared
3
Proof-of-Concept Milestones
First patient dosed + primary endpoint met
4
Pivotal Trial Milestones
Pivotal dosing + positive results (submission-ready)
5
Regulatory Approval
FDA + EMA (Europe) + PMDA (Japan) approvals
6
Commercial/Sales Milestones
Payments at $2B, $4B, $6B sales thresholds
7
Royalty/Profit-Share
20-25% of incremental operating profit during extension
💡
Example — Keytruda (Merck):
$50-60M signing + $15-25M pre-clinical + $85-130M PoC + $120-180M pivotal + $120-180M regulatory + $200-275M sales milestones = $590-850M in milestones before royalties even begin.

This means OptiRTP receives substantial cash payments throughout the development process — not just when drugs reach the market. Signing a single anchor partnership (e.g., Merck) could generate $50-60M in immediate revenue upon contract execution.

↑ Back to Top

Section 10: Keytruda — Staged Milestone Payments

[Source: OBST GTM Strategy Document, December 2025. Based on Merck-Eisai Lenvima benchmarks: $300M upfront, up to $5.76B milestones]

Why Merck Needs OBST for Keytruda:

  • Keytruda is Merck's flagship asset with ~US$29.5 billion in 2024 global sales — the world's best-selling drug
  • Primary US patent expiry in 2028 creates an urgent, high-value patent cliff
  • Fully patented with no biosimilars on market — ideal timing for OBST combination strategy
  • OBST extension opportunity: ~US$4.49B incremental NPV; OBST share ~US$1.12B
Stage Trigger Payment
Signing Contract execution $50–60M
Pre-clinical Protocol accepted; pre-IND meeting cleared $15–25M
PoC Dosing First patient dosed in controlled PoC trial $25–40M
PoC Positive Primary endpoint met (nausea ↓≥X%, ulcers ↓≥Y%) $60–90M
Pivotal Dosing First patient dosed in pivotal trial $40–60M
Pivotal Positive Pre-specified primary endpoint met; submission-ready $80–120M
FDA Approval Label includes OBST-enhanced regimen $80–120M
EMA + PMDA Major ex-US regulatory approvals $40–60M
Sales $2B OBST-combo segment reaches threshold $50–75M
Sales $4B OBST-combo segment reaches threshold $75–100M
Sales $6B OBST-combo segment reaches threshold $75–100M
TOTAL MILESTONES $590–850M
Royalty/Profit-Share 20–25% of incremental operating profit during extension ~$280–350M NPV
KEYTRUDA GRAND TOTAL ~$870M – $1.2B
📊 Platform Premium Benchmarks

OBST captures 11.64% of total extension value created — aligned with the 10-15% "platform premium" seen in comparable pharma deals.1

1 Merck-Eisai Lenvima collaboration ($300M upfront, up to $5.76B milestones); Otsuka-Click Therapeutics partnership ($10M upfront, $272M commercial milestones). Source: Blue Matter Consulting, "Deals Analysis: Biopharma 1H 2025".

↑ Back to Top

Section 11: Key Risks

Shareholders and potential partners should be aware of the following risks associated with the pharmaceutical partnership strategy:

  • No partnership agreements have been signed. All figures are projections.
  • Pharmaceutical companies may choose alternative strategies to address patent cliffs.
  • Clinical trials required for combination therapy patents may not achieve desired endpoints.
  • Regulatory approval for method-of-use patents is not guaranteed.
  • Timeline for any potential deal is uncertain and may extend beyond projections.
↑ Back to Top

Appendix: Sources & References

All data in this document has been verified against the following sources:

FDA & Clinical Data

  1. FDA. KEYTRUDA (pembrolizumab) Prescribing Information. Reference ID: 5309748. January 2024. accessdata.fda.gov/drugsatfda_docs/label/2024/125514s147lbl.pdf
  2. Merck & Co. Fourth-Quarter and Full-Year 2024 Financial Results. February 4, 2025. merck.com/news/
  3. WHO. PD-1/PD-L1 ICIs Financial Impact Report. Essential Medicines List Expert Committee 2025. cdn.who.int
  4. Zhang T, et al. Digital psychological interventions for physical symptoms in cancer patients: Systematic review and meta-analysis. Gen Hosp Psychiatry. 2023;84:47-59. PMID: 37385139
  5. ClinicalTrials.gov. Neuromodulatory digital therapeutic for breast cancer. NCT06136923
  6. Resonote BioTech. VA PLP Clinical Protocol. Validated by Lindus Health. November 2025.
  7. OBST GTM Strategy Document. Resonote BioTech Inc. December 2025.

Patent Cliff and Market Data

Patent Expiry Databases

Pharma Deal Benchmarks

📚
Note: OBST NPV calculations use the 5-year extension model with 15% revenue preservation, 32% net margin, and 8% discount rate. Milestone structures are benchmarked against the Merck-Eisai, Otsuka-Click, and Rani-Chugai deals as documented above.
↑ Back to Top

Contact

If you would like to discuss any information in this document, or any other matter relating to OBST, pharmaceutical partnerships, or investment opportunities, please do not hesitate to contact us directly.

Bogdan Anich - Founder / Director / CTO

Resonote BioTech Inc (DE, USA)

OptiRTP Limited (NZ)

Optimum Bio Innovations Limited (NZ)

Email: bogdan.anich@optirtp.com

Website: www.optirtp.com

Regulatory / FDA / Clinical

Sharyn Harper

Chief Operating Officer

Resonote BioTech Inc (DE, USA)

OptiRTP Limited (NZ)

Optimum Bio Innovations Limited (NZ)

Email: sharyn.harper@optirtp.com

Website: www.optirtp.com

↑ Back to Top

Document Classification

Classification: CONFIDENTIAL — For Internal Use and Authorized Partners Only

Prepared by: Resonote BioTech Inc. / OptiRTP Limited

Version: VERIFIED EDITION — December 2025

Data Verification: All data points in this document have been verified against primary sources as cited. This document is suitable for investor communications, regulatory submissions, and partnership discussions.